# Carbidopa + Levodopa

## Numient 48.75/195mg extended-release

| TAH Drug Code      | [ONUM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ONUM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Parkinson's disease， post-encephalitic Parkinsonian syndrome， symptomatic Parkinsonian syndrome (due to carbon monoxide or manganese toxicity).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Dose recommendations should be followed at initiation of treatment and adapted according to clinical response. Initial dose and titration in levodopa-naive patients: In the first 3 days， the initial dose is one capsule containing levodopa 95 mg and carbidopa 23.75 mg TID. Starting from the 4th day， the dose can be increased to one capsule containing levodopa 145 mg and carbidopa 36.25 mg TID. For patients who have not received levodopa treatment， limited experience exists with daily levodopa doses exceeding 1，170 mg. Numient is recommended to be taken orally 3 to 5 times per day. Maximum dose: 4 hard capsules 195 mg/48.75 mg TID. Each capsule's dosage can be taken individually or in combination with other capsules as needed. There is limited research on co-administration with other levodopa-containing medications. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to Numient or any component of the formulation. Narrow-angle glaucoma. Pheochromocytoma. Concurrent use with non-selective monoamine oxidase (MAO) inhibitors. These inhibitors must be discontinued at least two weeks before starting treatment. History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common: Vitamin B6 deficiency， Nausea (Enteral， 30%; oral， 5.5-5.7%)， Confusion (2.3-3.7%)， Dizziness (2.3-2.9%)， Headache (1.9-2%)， Peripheral neuropathy (Enteral， 8.7-30.4%) Serious: Myocardial infarction， Melanoma， Dyskinesia (Enteral， 14% ; oral， 12.2-28.4%)， Depression (Enteral， 11%; oral， 1.3-2.2%)， Hallucinations (Enteral; 5%; oral， 3.2-3.9%)， Suicidal thoughts， Neuroleptic malignant syndrome                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Sinemet 25/100mg

| TAH Drug Code      | [OSINM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSINM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Parkinson's disease and syndromes (muscle rigidity and bradykinesia， tremor， salivation， dysphagia， and postural instability).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | Initial， 1 tablet TID. Maximum : 8 tablets/day.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | SINEMET cannot be used together with nonselective MAO inhibitors (nonselective monoamine oxidase inhibitors). MAO inhibitors should be discontinued at least two weeks before starting SINEMET. SINEMET may be used concomitantly with MAO inhibitors that are selective for MAO type B (e.g. Selegiline HCl) at their recommended doses. SINEMET is contraindicated in patients who are allergic to any component of this product and suffer from narrow-angle glaucoma. In addition， because levodopa can activate malignant melanoma， SINEMET should also be contraindicated in patients with suspected undiagnosed skin lesions or patients with a history of melanoma. |
| Adverse Effects    | Dyskinesia including choreiform， dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% )                                                                                                                                                                                                                                                                                                                                                                                               |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

